Standout Papers

Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advance... 2016 2026 2019 2022 348
  1. Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer (2016)
    Naiyer A. Rizvi, Matthew D. Hellmann et al. Journal of Clinical Oncology

Immediate Impact

14 by Nobel laureates 6 from Science/Nature 70 standout
Sub-graph 1 of 21

Citing Papers

Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
2024 Standout
Nanomedicine Remodels Tumor Microenvironment for Solid Tumor Immunotherapy
2024 Standout
2 intermediate papers

Works of Allen C. Chen being referenced

Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: Interim phase I results.
2014
Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC.
2014

Author Peers

Author Last Decade Papers Cites
Allen C. Chen 726 385 3 272 13 828
Jayne S. Gurtler 640 256 2 259 10 727
Zhuoran Yao 630 212 5 247 17 772
Juan P. Fusco 479 169 3 410 15 740
Chuanyong Mu 746 344 2 367 23 934
Leslie Rozeboom 562 205 4 302 16 747
Maria Pilar Andueza 593 180 3 541 12 928
Mariacarla Andreozzi 597 403 2 172 19 789
Joris D. Veltman 338 282 22 289 21 709
Shamayel Mohammed 583 110 4 360 17 718
Miriam Paone 581 151 3 270 14 709

All Works

Loading papers...

Rankless by CCL
2026